| Monday, October 24, 2011, Day One |
| 10:30 - 12:00 PM |
Attendees are invited to move from room-to-room |
| Room |
Grand Ballroom EF |
Grand Ballroom CD |
| Session Title |
TR1. CONCURRENT PRESENTATION OF TOP-RANKED ABSTRACTS - 1 - DECISION PSYCHOLOGY AND QUANTITATIVE METHODS
Click to view session |
TR2. CONCURRENT PRESENTATION OF TOP-RANKED ABSTRACTS - 2 - HEALTH SERVICES, ECONOMICS AND POLICY
Click to view session |
| 10:30 - 10:48 |
TR1-1* (DEC) THE USE OF PERSUASION IN PRIMARY CARE VISITS..
TR1-1* (DEC) THE USE OF PERSUASION IN PRIMARY CARE VISITS AND ITS EFFECT ON ADHERENCE TO PHYSICIAN-RECOMMENDED COLORECTAL CANCER SCREENING
|
TR2-1 (ESP) COST-EFFECTIVENESS AND PUBLIC HEALTH/BUDGET-IM..
TR2-1 (ESP) COST-EFFECTIVENESS AND PUBLIC HEALTH/BUDGET-IMPACT OF FFR-GUIDED PCI IN MULTIVESSEL PATIENTS IN 6 EUROPEAN COUNTRIES - ANALYSIS ALONG THE FAME TRIAL DATA
|
| 10:48 - 11:06 |
TR1-2 (DEC) FACTORS INFLUENCING PHYSICIANS' THERAPEUTIC..
TR1-2 (DEC) FACTORS INFLUENCING PHYSICIANS' THERAPEUTIC DECISION WHEN PRESCRIBING CHEMOTHERAPY: A DISCRETE CHOICE EXPERIMENT
|
TR2-2* (ESP) EFFECTIVENESS AND COST EFFECTIVENESS OF ORAL..
TR2-2* (ESP) EFFECTIVENESS AND COST EFFECTIVENESS OF ORAL PRE-EXPOSURE PROPHYLAXIS FOR INJECTION DRUG USERS IN MIXED HIV EPIDEMICS
|
| 11:06 - 11:24 |
TR1-3 (DEC) ANXIETY AS AN IMPETUS FOR ACTION: ON THE..
TR1-3 (DEC) ANXIETY AS AN IMPETUS FOR ACTION: ON THE RELATIVE INFLUENCE OF BREAST CANCER RISK AND BREAST CANCER ANXIETY ON CHEMOPREVENTION DECISIONS
|
TR2-3* (ESP) INTERNAL VALIDATION AND CALIBRATION OF A MODEL..
TR2-3* (ESP) INTERNAL VALIDATION AND CALIBRATION OF A MODEL TO FORECAST HIV TREATMENT DEMAND AND CAPACITY IN HAITI
|
| 11:24 - 11:42 |
TR1-4 (BEC) COMMITMENT TO EXERCISE: NUDGED TO EXERCISE? OR..
TR1-4 (BEC) COMMITMENT TO EXERCISE: NUDGED TO EXERCISE? OR TO REVEAL YOUR TRUE COLORS?
|
TR2-4 (ESP) GENE EXPRESSION PROFILING FOR GUIDING ADJUVANT..
TR2-4 (ESP) GENE EXPRESSION PROFILING FOR GUIDING ADJUVANT CHEMOTHERAPY DECISIONS IN WOMEN WITH EARLY BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS OF 1000 STRATEGIES FOR THE PROVISION OF ADJUVANT! ONLINE, 21-GENE ASSAY AND CHEMOTHERAPY
|
| 11:42 - 12:00 |
TR1-5* (MET) MODELING MEDICATION ADHERENCE BEHAVIOR IN..
TR1-5* (MET) MODELING MEDICATION ADHERENCE BEHAVIOR IN COST-EFFECTIVENESS ANALYSIS: THE JUPITER EXAMPLE
|
TR2-5 (ESP) ESTIMATING UTILITIES FOR CHRONIC KIDNEY..
TR2-5 (ESP) ESTIMATING UTILITIES FOR CHRONIC KIDNEY DISEASE IN PATIENTS WITH TYPE 2 DIABETES USING TRANSFORMED SF-36 AND SF-12 RESPONSES: CHALLENGES IN A VETERAN POPULATION
|
| 1:30 - 3:00 PM |
Attendees are invited to move from room-to-room |
| Room |
Grand Ballroom EF |
Grand Ballroom CD |
Columbus Hall C-F |
Columbus Hall AB |
| Session Title |
A. DECISION PSYCHOLOGY LUSTED FINALISTS
Click to view session |
B. HEALTH TECHNOLOGY AND OUTCOMES RESEARCH
Click to view session |
C. MODELING AND SIMULATION METHODS
Click to view session |
BD1. INVITED SESSION: ETHICS AND BEHAVIORAL ECONOMICS in MEDICINE
Click to view session |
| 1:30 - 1:45 |
A-1* (DEC) PATIENT PARTICIPATION IN DECISION MAKING ABOUT..
A-1* (DEC) PATIENT PARTICIPATION IN DECISION MAKING ABOUT DISEASE MODIFYING ANTI-RHEUMATIC DRUGS: PERCEIVED AND PREFERRED ROLES OF PATIENTS
|
B-1 (ESP) ADHERENCE WITH COLORECTAL CANCER SCREENING:..
B-1 (ESP) ADHERENCE WITH COLORECTAL CANCER SCREENING: DOES THE WAY YOU MODEL IT MATTER?
|
C-1 (MET) DEVELOPING A COMPLEX AGENT NETWORK MODEL TO..
C-1 (MET) DEVELOPING A COMPLEX AGENT NETWORK MODEL TO PREDICT HIV AND HCV INCIDENCE IN CANADA
|
BD1-1 (BEC) 1:30 - 1:53 PM - INTEGRATING ETHICS INTO THE..
BD1-1 (BEC) 1:30 - 1:53 PM - INTEGRATING ETHICS INTO THE SCIENCE OF BEHAVIOR CHANGE
|
| 1:45 - 2:00 |
A-2* (DEC) INACCURATE EXPECTATIONS? AFFECTIVE FORECASTING..
A-2* (DEC) INACCURATE EXPECTATIONS? AFFECTIVE FORECASTING IN THE CONTEXT OF ELECTIVE HYSTERECTOMY
|
B-2 (ESP) A PRAGMATIC APPROACH FOR ASSESSING PREDICTORS..
B-2 (ESP) A PRAGMATIC APPROACH FOR ASSESSING PREDICTORS OF MEDICATION ADHERENCE
|
C-2 (MET) GETTING THE BEST OF BOTH WORLDS: AN APPROACH..
C-2 (MET) GETTING THE BEST OF BOTH WORLDS: AN APPROACH FOR MAXIMISING INTERNAL AND EXTERNAL VALIDITY IN COST-EFECTIVENESS STUDIES
|
BD1-2 (BEC) 1:53 - 2:15 PM - ETHICAL DEFENSE OF A NUDGE..
BD1-2 (BEC) 1:53 - 2:15 PM - ETHICAL DEFENSE OF A NUDGE TOWARDS FECAL OCCULT BLOOD TESTING FOR COLORECTAL CANCER SCREENING
|
| 2:00 - 2:15 |
A-3* (DEC) EFFECTS OF DECISION AIDS ON DECISIONAL..
A-3* (DEC) EFFECTS OF DECISION AIDS ON DECISIONAL CONFLICT ASSOCIATED WITH OSTEOARTHRITIS TREATMENT
|
B-3 (ESP) INVESTMENT AND DISINVESTMENT OF HEALTH..
B-3 (ESP) INVESTMENT AND DISINVESTMENT OF HEALTH TECHNOLOGIES: THE NEED FOR TWO COST-EFFECTIVENESS THRESHOLDS
|
C-3 (MET) ANALYTICAL SOLUTION METHODS FOR CONTINUOUS-TIM..
C-3 (MET) ANALYTICAL SOLUTION METHODS FOR CONTINUOUS-TIME MARKOV AND SEMI-MARKOV MODELS
|
BD1-3 (BEC) 2:15 - 2:38 PM - COMPARATIVE ETHICS OF..
BD1-3 (BEC) 2:15 - 2:38 PM - COMPARATIVE ETHICS OF FINANCIAL INCENTIVES FOR HEALTH PROMOTION
|
| 2:15 - 2:30 |
A-4* (DEC) THE WEIGHT OF HISTORY: CAPTURING PROSTATE..
A-4* (DEC) THE WEIGHT OF HISTORY: CAPTURING PROSTATE CANCER RISK AND SCREENING POLICIES FOR MEN WITH AND WITHOUT A FAMILY HISTORY USING A POLICY-CAPTURING APPROACH
|
B-4 (ESP) COMPARATIVE EFFECTIVENESS RESEARCH AND..
B-4 (ESP) COMPARATIVE EFFECTIVENESS RESEARCH AND TECHNOLOGICAL ABANDONMENT
|
C-4 (MET) TRANSFORMATION OF TRANSITION RATES AND..
C-4 (MET) TRANSFORMATION OF TRANSITION RATES AND PROBABILITIES IN DISCRETE-TIME MARKOV CHAINS: WHAT ABOUT COMPETING RISKS?
|
BD1-4 (BEC) 2:38 - 3:00 PM - ETHICS AND BEHAVIORAL..
BD1-4 (BEC) 2:38 - 3:00 PM - ETHICS AND BEHAVIORAL ECONOMICS IN MEDICINE DISCUSSION
|
| 2:30 - 2:45 |
A-5* (DEC) ASSESING PATIENTS' INVOLVEMENT IN DECISION-MAK..
A-5* (DEC) ASSESING PATIENTS' INVOLVEMENT IN DECISION-MAKING DURING A NUTRITIONNAL CONSULTATION WITH A DIETITIAN
|
B-5 (ESP) A FRAMEWORK FOR MEASURING THE VALUE OF QUALITY..
B-5 (ESP) A FRAMEWORK FOR MEASURING THE VALUE OF QUALITY IMPROVEMENT
|
C-5 (MET) HALF-CYCLE CORRECTION AND SIMPSON'S METHOD..
C-5 (MET) HALF-CYCLE CORRECTION AND SIMPSON'S METHOD TESTED IN REAL HEALTH ECONOMIC MODELS – DOES IT MATTER WHICH METHOD WE USE?
|
|
| 2:45 - 3:00 |
A-6* (BEC) REWARD SENSITIVITY, TEMPORAL DISCOUNTING,..
A-6* (BEC) REWARD SENSITIVITY, TEMPORAL DISCOUNTING, GENDER AND RISKY HEALTH BEHAVIORS: A FUZZY-TRACE THEORY APPROACH
|
B-6 (ESP) HISTORICAL CONTROLS FOR MORTALITY: R.I.P
B-6 (ESP) HISTORICAL CONTROLS FOR MORTALITY: R.I.P
|
C-6 (MET) ACCOUNTING FOR UNCERTAINTY IN THE AFFECTED..
C-6 (MET) ACCOUNTING FOR UNCERTAINTY IN THE AFFECTED POPULATION USED IN VALUE OF INFORMATION ANALYSES: AN APPLICATION IN ADVANCED BILIARY TRACT CANCER
|
|
| 4:30 - 6:00 PM |
Attendees are invited to move from room-to-room |
| Room |
Grand Ballroom EF |
Grand Ballroom CD |
Columbus Hall C-F |
Columbus Hall AB |
| Session Title |
D. SHARED DECISION MAKING AND PATIENT-PHYSICIAN COMMUNICATION
Click to view session |
E. HEALTH ECONOMICS LUSTED FINALISTS
Click to view session |
F. BEHAVIORAL ECONOMIC AND DECISION PSYCHOLOGY APPROACHES TO CHOICE
Click to view session |
BD2. INVITED SESSION: ISPOR-SMDM MODELING GOOD RESEARCH PRACTICES TASK FORCE UPDATE
Click to view session |
| 4:30 - 4:45 |
D-1 (DEC) TOWARD MINIMUM STANDARDS FOR THE CERTIFICATION..
D-1 (DEC) TOWARD MINIMUM STANDARDS FOR THE CERTIFICATION OF PATIENT DECISION AIDS: A CORRELATION ANALYSIS AND MODIFIED DELPHI CONSENSUS PROCESS
|
E-1* (ESP) THE COST-EFFECTIVENESS OF SYMPTOM-BASED..
E-1* (ESP) THE COST-EFFECTIVENESS OF SYMPTOM-BASED TESTING AND ROUTINE SCREENING FOR ACUTE HIV INFECTION IN MEN WHO HAVE SEX WITH MEN IN THE UNITED STATES
|
F-1 (BEC) TRADING OFF LIFE STYLE OPTIONS TO REDUCE THE..
F-1 (BEC) TRADING OFF LIFE STYLE OPTIONS TO REDUCE THE RISK OF CHD IN NORTHERN IRELAND
|
BD2-1 (BEC) TASK FORCE UPDATE
BD2-1 (BEC) TASK FORCE UPDATE
|
| 4:45 - 5:00 |
D-2 (DEC) WHO IS GUIDING DECISIONS ABOUT WHETHER TO..
D-2 (DEC) WHO IS GUIDING DECISIONS ABOUT WHETHER TO PERFORM PEDIATRIC GASTRIC FUNDOPLICATION?
|
E-3* (ESP) OPTIMAL HIV TESTING BY RISK GROUP
E-3* (ESP) OPTIMAL HIV TESTING BY RISK GROUP
|
F-2 (BEC) IGNORANCE IS BLISS: WHY DO PATIENTS AT RISK..
F-2 (BEC) IGNORANCE IS BLISS: WHY DO PATIENTS AT RISK FOR HUNTINGTON DISEASE AVOID GENETIC TESTING?
|
|
| 5:00 - 5:15 |
D-3 (DEC) BELIEFS ABOUT COMMUNICATING WITH A PHYSICIAN..
D-3 (DEC) BELIEFS ABOUT COMMUNICATING WITH A PHYSICIAN ABOUT MEDICAL DECISIONS: DISTINGUISHING BETWEEN EXCHANGING INFORMATION AND MAKING A CHOICE
|
E-4* (ESP) COST-EFFECTIVENESS OF RISK-FACTOR GUIDED AND..
E-4* (ESP) COST-EFFECTIVENESS OF RISK-FACTOR GUIDED AND UNIVERSAL SCREENING FOR CHRONIC HEPATITIS C INFECTION IN THE U.S
|
F-3 (BEC) METABOLIC MECHANISMS OF INTERTEMPORAL CHOICE:..
F-3 (BEC) METABOLIC MECHANISMS OF INTERTEMPORAL CHOICE: BLOOD GLUCOSE AND DELAY DISCOUNTING
|
|
| 5:15 - 5:30 |
D-4 (DEC) IMPLEMENTING SHARED DECISION MAKING IN A..
D-4 (DEC) IMPLEMENTING SHARED DECISION MAKING IN A MULTICULTURAL PRACTICE: A COLLABORATIVE PRIMARY CARE-HEALTH EDUCATOR APPROACH
|
E-5* (ESP) THE COST-EFFECTIVENESS OF PREEXPOSURE..
E-5* (ESP) THE COST-EFFECTIVENESS OF PREEXPOSURE PROPHYLAXIS FOR HIV PREVENTION IN MEN WHO HAVE SEX WITH MEN IN THE UNITED STATES
|
F-4 (BEC) A RANDOMIZED TRIAL OF DEFAULT OPTIONS IN..
F-4 (BEC) A RANDOMIZED TRIAL OF DEFAULT OPTIONS IN ADVANCE DIRECTIVES FOR PATIENTS WITH TERMINAL LUNG DISEASES
|
|
| 5:30 - 5:45 |
D-5 (DEC) FACILITATORS AND BARRIERS TO IMPLEMENTING..
D-5 (DEC) FACILITATORS AND BARRIERS TO IMPLEMENTING SHARED DECISION MAKING IN A PRIMARY CARE DEMONSTRATION
|
E-6* (ESP) SOCIAL INTERACTION MODULES IN EPIDEMIC MODELS..
E-6* (ESP) SOCIAL INTERACTION MODULES IN EPIDEMIC MODELS FOR THE SIMULATION OF INFECTIOUS DISEASES AND EVALUATION OF INTERVENTIONS
|
F-5 (DEC) “NUDGING” PATIENTS TOWARDS ACCEPTING STRONG..
F-5 (DEC) “NUDGING” PATIENTS TOWARDS ACCEPTING STRONG RECOMMENDATIONS
|
|
| 5:45 - 6:00 |
D-6 (DEC) EVALUATING ASSOCIATIONS BETWEEN PATIENT..
D-6 (DEC) EVALUATING ASSOCIATIONS BETWEEN PATIENT PREFERENCES FOR COLORECTAL CANCER SCREENING TESTS AND THE CONTENT OF PATIENT-PHYSICIAN DISCUSSIONS
|
|
F-6 (DEC) CAN THE RESULTS OF LABORATORY BASED MESSAGE..
F-6 (DEC) CAN THE RESULTS OF LABORATORY BASED MESSAGE FRAMING EXPERIMENTS BE GENERALIZED TO PATIENTS?
|
|
| Tuesday, October 25, 2011, Day Two |
| 10:00 - 11:30 AM |
Attendees are invited to move from room-to-room |
| Room |
Grand Ballroom EF |
Grand Ballroom CD |
Columbus Hall C-F |
| Session Title |
G. VALUES, PREFERENCE ELICITATION AND UTILITY ASSESSMENT
Click to view session |
H. COST-EFFECTIVENESS ANALYSIS AND ECONOMIC EVALUATION
Click to view session |
I. INNOVATIVE METHODS LUSTED FINALISTS
Click to view session |
| 10:00 - 10:15 |
G-1 (DEC) EFFECT OF CHRONIC CONDITIONS ON THE VALUATION..
G-1 (DEC) EFFECT OF CHRONIC CONDITIONS ON THE VALUATION OF HYPOTHETICAL EQ-5D HEALTH STATES
|
H-1* (ESP) COST-EFFECTIVENESS OF PRIMARY HUMAN PAPILLOMAV..
H-1* (ESP) COST-EFFECTIVENESS OF PRIMARY HUMAN PAPILLOMAVIRUS (HPV) TESTING IN NORWAY
|
I-1* (MET) APPLYING DOUBLY ROBUST METHODS IN THE CONTEXT..
I-1* (MET) APPLYING DOUBLY ROBUST METHODS IN THE CONTEXT OF COST-EFFECTIVENESS ANALYSIS
|
| 10:15 - 10:30 |
G-2 (DEC) COMPARATIVE PERFORMANCE OF CONJOINT ANALYSIS,..
G-2 (DEC) COMPARATIVE PERFORMANCE OF CONJOINT ANALYSIS, TIME TRADE OFF, AND RATING SCALE METHODS OF PREFERENCE ASSESSMENT: PILOT DATA FROM A STUDY OF MEN AT RISK FOR PROSTATE CANCER
|
H-2* (ESP) COST-EFFECTIVENESS OF USING TRANEXAMIC ACID..
H-2* (ESP) COST-EFFECTIVENESS OF USING TRANEXAMIC ACID INFUSION IN TRAUMA PATIENTS WITH SIGNIFICANT HEMORRHAGE
|
I-2* (MET) DECISIONS, DECISIONS: CAN DIRECT-SEARCH..
I-2* (MET) DECISIONS, DECISIONS: CAN DIRECT-SEARCH OPTIMIZATION OF CONTINUOUS DECISION VARIABLES RESULT IN SUBSTANTIAL WELFARE GAINS COMPARED TO USUAL METHODS?
|
| 10:30 - 10:45 |
G-3 (DEC) PREDICTING UTILITY SCORES FOR PROSTATE CANCER:..
G-3 (DEC) PREDICTING UTILITY SCORES FOR PROSTATE CANCER: MAPPING THE PROSTATE CANCER INDEX TO THE PATIENT ORIENTED PROSTATE UTILITY SCALE (PORPUS)
|
H-3* (ESP) COST-EFFECTIVENESS OF OMALIZUMAB FOR THE..
H-3* (ESP) COST-EFFECTIVENESS OF OMALIZUMAB FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE PERSISTENT ASTHMA: RESULTS FROM A RANDOMIZED CONTROLLED TRIAL IN JAPAN
|
I-3* (MET) APPLYING THE PAYOFF TIME FRAMEWORK TO CAROTID..
I-3* (MET) APPLYING THE PAYOFF TIME FRAMEWORK TO CAROTID DISEASE MANAGEMENT
|
| 10:45 - 11:00 |
G-4 (DEC) SPILLOVER DISUTILITY OF CHRONIC CONDITIONS IN..
G-4 (DEC) SPILLOVER DISUTILITY OF CHRONIC CONDITIONS IN US: MENTAL DISORDERS HAVE GREATEST EFFECT ON FAMILY MEMBERS
|
H-4 (ESP) COST-EFFECTIVENESS OF SCREENING STRATEGIES FOR..
H-4 (ESP) COST-EFFECTIVENESS OF SCREENING STRATEGIES FOR PEDIATRIC DYSGLYCEMIA
|
I-4* (MET) EVALUATING THE ROLE OF ASPIRIN FOR CARDIOVASCU..
I-4* (MET) EVALUATING THE ROLE OF ASPIRIN FOR CARDIOVASCULAR RISK MANAGEMENT FOR PATIENTS WITH TYPE 2 DIABETES
|
| 11:00 - 11:15 |
G-5 (DEC) PREFERENCES FOR BREAST CANCER CHEMOPREVENTION
G-5 (DEC) PREFERENCES FOR BREAST CANCER CHEMOPREVENTION
|
H-5 (ESP) A PORTFOLIO APPROACH TO HIV CONTROL IN SOUTH..
H-5 (ESP) A PORTFOLIO APPROACH TO HIV CONTROL IN SOUTH AFRICA
|
I-5* (MET) USING AGENT-BASED SIMULATION TO EVALUATE..
I-5* (MET) USING AGENT-BASED SIMULATION TO EVALUATE POLICIES FOR CLOSTRIDIUM DIFFICILE INFECTION CONTROL IN A HOSPITAL
|
| 11:15 - 11:30 |
G-6 (DEC) ATTRIBUTE PROCESSING IN CHOICE EXPERIMENTS: A..
G-6 (DEC) ATTRIBUTE PROCESSING IN CHOICE EXPERIMENTS: A METHODOLOGICAL EXPLORATION
|
H-6* (ESP) USE OF DEDICATED WINGS TO MAXIMIZE INSTITUTION..
H-6* (ESP) USE OF DEDICATED WINGS TO MAXIMIZE INSTITUTIONAL OBJECTIVES UNDER STRAINED BED CAPACITY
|
I-6 (MET) EXPECTED UTILITY MODEL USED TO COMPARE THE..
I-6 (MET) EXPECTED UTILITY MODEL USED TO COMPARE THE VALUE OF SCREENING VERSUS DIAGNOSTIC MAMMOGRAPHY
|
| 1:00 - 2:30 PM |
Attendees are invited to move from room-to-room |
| Room |
Grand Ballroom EF |
Grand Ballroom CD |
Columbus Hall C-F |
| Session Title |
J. RISK COMMUNICATION AND RISK PERCEPTION
Click to view session |
K. HEALTH POLICY AND OUTCOMES RESEARCH in CANCER
Click to view session |
L. HEALTH ECONOMICS LUSTED FINALISTS.
Click to view session |
| 1:00 - 1:15 |
J-1 (DEC) THE EFFECT OF NARRATIVE CONTENT AND EMOTIONAL..
J-1 (DEC) THE EFFECT OF NARRATIVE CONTENT AND EMOTIONAL VALENCE ON DECISIONS ABOUT TREATMENTS FOR EARLY STAGE BREAST CANCER
|
K-1 (ESP) COST-EFFECTIVENESS OF ALTERNATING MRI AND..
K-1 (ESP) COST-EFFECTIVENESS OF ALTERNATING MRI AND DIGITAL MAMMOGRAPHY FOR SCREENING BRCA1 AND BRCA2 GENE MUTATION CARRIERS
|
L-1* (ESP) OPTIMAL SURVEILLANCE SCHEDULES FOR LOW RISK..
L-1* (ESP) OPTIMAL SURVEILLANCE SCHEDULES FOR LOW RISK BLADDER CANCER PATIENTS
|
| 1:15 - 1:30 |
J-2 (DEC) AVATARS AND ANIMATION OF RANDOMNESS IN RISK..
J-2 (DEC) AVATARS AND ANIMATION OF RANDOMNESS IN RISK GRAPHICS HELP PEOPLE BETTER UNDERSTAND THEIR RISK OF CARDIOVASCULAR DISEASE
|
K-2 (ESP) BENEFITS AND HARMS OF MAMMOGRAPHY SCREENING..
K-2 (ESP) BENEFITS AND HARMS OF MAMMOGRAPHY SCREENING AFTER AGE 74 YEARS: ESTIMATES OF OVERDIAGNOSIS
|
L-2* (ESP) ESTIMATING THE COST OF NO-SHOWS AND EVALUATING..
L-2* (ESP) ESTIMATING THE COST OF NO-SHOWS AND EVALUATING THE EFFECTS OF MITIGATION STRATEGIES
|
| 1:30 - 1:45 |
J-3 (DEC) LITERACY AND IRRATIONAL DECISIONS: BIAS FROM..
J-3 (DEC) LITERACY AND IRRATIONAL DECISIONS: BIAS FROM BELIEFS, NOT FROM COMPREHENSION
|
K-3 (ESP) COST-EFFECTIVENESS OF EPIDERMAL GROWTH FACTOR..
K-3 (ESP) COST-EFFECTIVENESS OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION TESTING FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER LIVING IN ONTARIO, CANADA
|
L-3* (ESP) A TRIAL OF LABOR AFTER CESAREAN DECISION..
L-3* (ESP) A TRIAL OF LABOR AFTER CESAREAN DECISION ANALYSIS: THE IMPACT OF FUTURE PREGNANCIES
|
| 1:45 - 2:00 |
J-4 (DEC) DISGUSTING MEDICAL OUTCOMES FEEL MORE LIKELY..
J-4 (DEC) DISGUSTING MEDICAL OUTCOMES FEEL MORE LIKELY THAN THEY REALLY ARE
|
K-4 (ESP) COST-EFFECTIVENESS OF A NOVEL PROSTATE CANCER..
K-4 (ESP) COST-EFFECTIVENESS OF A NOVEL PROSTATE CANCER DETECTION INDEX FROM A MANAGED CARE PAYER PROSPECTIVE
|
L-4* (ESP) MODELING CARE UTILIZATION RATIOS TO GUIDE..
L-4* (ESP) MODELING CARE UTILIZATION RATIOS TO GUIDE SURGE RESPONSES FOR NON-CRISIS EVENTS
|
| 2:00 - 2:15 |
J-5 (DEC) INTEGERS ARE BETTER: ADDING DECIMALS TO RISK..
J-5 (DEC) INTEGERS ARE BETTER: ADDING DECIMALS TO RISK ESTIMATES MAKES THEM LESS BELIEVABLE AND HARDER TO REMEMBER
|
K-5 (ESP) COMPARING LIFETIME OUTCOMES FOR IMMEDIATE..
K-5 (ESP) COMPARING LIFETIME OUTCOMES FOR IMMEDIATE SURGERY VERSUS ACTIVE SURVEILLANCE FOR LOW RISK PROSTATE CANCER USING A THREE-PART MODEL
|
L-5* (ESP) THE COST-EFFECTIVENESS OF IMPROVEMENTS IN..
L-5* (ESP) THE COST-EFFECTIVENESS OF IMPROVEMENTS IN PREHOSPITAL TRAUMA TRIAGE IN THE U.S
|
| 2:15 - 2:30 |
J-6 (DEC) FEASIBILITY OF A WEB-BASED TREATMENT DECISION..
J-6 (DEC) FEASIBILITY OF A WEB-BASED TREATMENT DECISION TOOL FOR OLDER PATIENTS WITH DIABETES
|
K-6 (ESP) QUANTITATIVE FECAL OCCULT BLOOD TESTING TO..
K-6 (ESP) QUANTITATIVE FECAL OCCULT BLOOD TESTING TO SCREEN FOR COLORECTAL CANCER: POTENTIAL ADVANTAGE OF LOWERING THE POSITIVITY THRESHOLD AND EXTENDING THE SCREENING INTERVAL
|
L-6* (ESP) TRANSCATHETER AORTIC VALVE IMPLANTATION SHOULD..
L-6* (ESP) TRANSCATHETER AORTIC VALVE IMPLANTATION SHOULD CHANGE THE MANAGEMENT OF NON-SURGICAL AORTIC STENOSIS CANDIDATES
|
| Wednesday, October 26, 2011, Day Three |
| 10:15 - 11:45 AM |
Attendees are invited to move from room-to-room |
| Room |
Grand Ballroom EF |
Grand Ballroom CD |
Columbus Hall C-F |
| Session Title |
M. DECISION AIDS AND DECISION SUPPORT
Click to view session |
N. METHODS TO PROMOTE CVD AND DIABETES PREVENTION
Click to view session |
O. METHODS FOR COMPARATIVE EFFECTIVENESS AND COST-EFFECTIVENESS RESEARCH
Click to view session |
| 10:15 - 10:30 |
M-1 (DEC) SHARED DECISION MAKING? EXAMINING MOTHER AND..
M-1 (DEC) SHARED DECISION MAKING? EXAMINING MOTHER AND DAUGHTER INFLUENCE ON THE CHOICE TO VACCINATE AGAINST THE HUMAN PAPILLOMAVIRUS
|
N-1 (ESP) DRONEDARONE COST OFFSET ACHIEVED BY REDUCTION..
N-1 (ESP) DRONEDARONE COST OFFSET ACHIEVED BY REDUCTION OF ATRIAL FIBRILLATION/FLUTTER PATIENT HOSPITALIZATION: RESULTS FROM THE FIRST 12 MONTHS OF FOLLOW-UP DURING THE ATHENA TRIAL
|
O-1 (ESP) YOU CAN'T GET HERE FROM THERE: METHODS FOR..
O-1 (ESP) YOU CAN'T GET HERE FROM THERE: METHODS FOR COST CONVERSION BETWEEN HEALTH CARE SYSTEMS NEED TO BE REEXAMINED
|
| 10:30 - 10:45 |
M-2 (DEC) PERSONALIZED DECISION SUPPORT FOR BREAST..
M-2 (DEC) PERSONALIZED DECISION SUPPORT FOR BREAST CANCER PREVENTION
|
N-2 (ESP) COST-EFFECTIVENESS OF NON-INVASIVE CARDIAC..
N-2 (ESP) COST-EFFECTIVENESS OF NON-INVASIVE CARDIAC IMAGING TECHNOLOGIES IN OUTPATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE
|
O-2 (ESP) DIFFERENCES BETWEEN MICRO-COSTING AND..
O-2 (ESP) DIFFERENCES BETWEEN MICRO-COSTING AND IMPLEMENTATION COSTS: EXAMPLE OF HIV RAPID TESTING AND COUNSELING IN A SUBSTANCE ABUSE TREATMENT PROGRAM
|
| 10:45 - 11:00 |
M-3 (DEC) IMPROVING PATIENT PARTICIPATION IN DECISION..
M-3 (DEC) IMPROVING PATIENT PARTICIPATION IN DECISION MAKING FOR ATRIAL FIBRILLATION
|
N-3* (ESP) USING A WEB-BASED SELF-ASSESSMENT TOOL TO..
N-3* (ESP) USING A WEB-BASED SELF-ASSESSMENT TOOL TO DETECT AND TREAT HYPERCHOLESTEROLAEMIA: THE COST–EFFECTIVENESS OF THE HEARTAWARE RISK FACTOR SCREENING PROGRAM
|
O-3 (ESP) SYSTEMATIZING THE USE OF VALUE OF INFORMATION..
O-3 (ESP) SYSTEMATIZING THE USE OF VALUE OF INFORMATION ANALYSIS FOR PRIORITIZING SYSTEMATIC REVIEWS
|
| 11:00 - 11:15 |
M-4 (DEC) INFORMED DECISION MAKING ABOUT BREAST CANCER..
M-4 (DEC) INFORMED DECISION MAKING ABOUT BREAST CANCER CHEMOPREVENTION: RCT OF AN ONLINE DECISION AID INTERVENTION
|
N-4 (ESP) OPTIMAL CUT-POINT OF DIABETES RISK SCORES TO..
N-4 (ESP) OPTIMAL CUT-POINT OF DIABETES RISK SCORES TO IDENTIFY UNDIAGNOSED DIABETES: A COST-EFFECTIVENESS PERSPECTIVE
|
O-4 (ESP) POPULATION SCREENING TRADE OFFS: A SYSTEMATIC..
O-4 (ESP) POPULATION SCREENING TRADE OFFS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF SCREENING ASYMPTOMATIC CHILDREN FOR CARDIAC DISORDERS THAT CAUSE SUDDEN CARDIAC DEATH
|
| 11:15 - 11:30 |
M-5 (DEC) DO INFORMED CONSENT DOCUMENTS MAKE GOOD..
M-5 (DEC) DO INFORMED CONSENT DOCUMENTS MAKE GOOD DECISION AIDS?
|
N-5 (ESP) ANATOMIC VS. FUNCTIONAL TESTING IN PATIENTS..
N-5 (ESP) ANATOMIC VS. FUNCTIONAL TESTING IN PATIENTS WITH STABLE CHRONIC CHEST PAIN SYNDROME AND THE EFFECT OF NON-OBSTRUCTIVE CORONARY ARTERY DISEASE – A COST-EFFECTIVENESS ANALYSIS
|
O-5 (ESP) USING LARGE ADMINISTRATIVE DATASETS AND CHART..
O-5 (ESP) USING LARGE ADMINISTRATIVE DATASETS AND CHART REVIEWS TO ESTIMATE COSTS FOR HEALTH STATES: THE CASE OF PROSTATE CANCER
|
| 11:30 - 11:45 |
M-6 (DEC) A PATH MODEL OF FACTORS THAT INFLUENCE..
M-6 (DEC) A PATH MODEL OF FACTORS THAT INFLUENCE SATISFACTION WITH DECISION SUPPORT AMONG SURROGATE DECISION MAKERS OF THE CHRONICALLY CRITICALLY ILL
|
N-6 (ESP) EVIDENCE-BASED PREVENTIVE SERVICE DELIVERY AND..
N-6 (ESP) EVIDENCE-BASED PREVENTIVE SERVICE DELIVERY AND MISSED OPPORTUNITIES DURING PERIODIC HEALTH EXAMINATIONS
|
O-6 (ESP) EXPLOITING LARGE OBSERVATIONAL DATA SETS FOR..
O-6 (ESP) EXPLOITING LARGE OBSERVATIONAL DATA SETS FOR COMPARATIVE EFFECTIVENESS RESEARCH: THE EXAMPLE OF HIP REPLACEMENT
|
